KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Work In Process: 2018-2025

Historic Work In Process for Twist Bioscience (TWST) over the last 8 years, with Sep 2025 value amounting to $2.3 million.

  • Twist Bioscience's Work In Process rose 5.55% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 5.55%. This contributed to the annual value of $2.3 million for FY2025, which is 5.55% up from last year.
  • According to the latest figures from FY2025, Twist Bioscience's Work In Process is $2.3 million, which was up 5.55% from $2.1 million recorded in FY2024.
  • Twist Bioscience's Work In Process' 5-year high stood at $4.8 million during FY2021, with a 5-year trough of $1.1 million in FY2023.
  • Its 3-year average for Work In Process is $1.8 million, with a median of $2.1 million in 2024.
  • Per our database at Business Quant, Twist Bioscience's Work In Process spiked by 139.34% in 2021 and then tumbled by 61.17% in 2023.
  • Twist Bioscience's Work In Process (Yearly) stood at $4.8 million in 2021, then slumped by 40.75% to $2.9 million in 2022, then slumped by 61.17% to $1.1 million in 2023, then soared by 92.81% to $2.1 million in 2024, then increased by 5.55% to $2.3 million in 2025.